Simulations PlusSLP
About: Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
Employees: 247
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
298% more call options, than puts
Call options by funds: $179K | Put options by funds: $45K
39% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 44
3% less funds holding
Funds holding: 175 [Q2] → 169 (-6) [Q3]
5.47% less ownership
Funds ownership: 82.44% [Q2] → 76.97% (-5.47%) [Q3]
17% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 36
38% less capital invested
Capital invested by funds: $801M [Q2] → $493M (-$308M) [Q3]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Stephens & Co. Jeff Garro 43% 1-year accuracy 3 / 7 met price target | 36%upside $39 | Overweight Initiated | 15 Nov 2024 |
BTIG David Larsen 41% 1-year accuracy 7 / 17 met price target | 75%upside $50 | Buy Maintained | 24 Oct 2024 |
Financial journalist opinion
Based on 3 articles about SLP published over the past 30 days
